SGLT2 inhibitors and length of stay in pregnant women: A multicentre observational study
Published
April 13, 2026
Paper ID
PAP-000240
Status
Published
DOI
10.65712/tmj.test000498
Advance Services
Abstract
Background: length of stay remains a leading cause of avoidable harm among pregnant women. Methods: We conducted a multicentre observational study across 3 centres between 2018 and 2024. Results: 3230 participants were included (median age 54 years). Serious adverse events were rare and similar between groups. Conclusion: Future work should test SGLT2 inhibitors in a pragmatic multicentre trial.
Introduction
The cost of length of stay to health systems is substantial. Earlier studies of SGLT2 inhibitors were small or single-centre.
The cost of length of stay to health systems is substantial. Practice around SGLT2 inhibitors varies widely between centres.
Guidelines make only a weak recommendation on SGLT2 inhibitors. length of stay remains a leading cause of avoidable harm among pregnant women. The cost of length of stay to health systems is substantial.
Materials and Methods
Missing data were handled with multiple imputation.
The primary outcome was length of stay, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity.
Results
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.62 (95% CI 0.33 to 0.66). 2980 participants were included (median age 78 years). 2104 participants were included (median age 31 years).
length of stay occurred in 18% of the intervention group versus 32% of controls. Serious adverse events were rare and similar between groups.
The adjusted odds ratio was 0.85 (95% CI 0.44 to 0.61). Effects were consistent across prespecified subgroups.
| Group | n | Events | Rate % |
|---|---|---|---|
| Control | 51 | 20 | 40.8 |
| Male | 213 | 48 | 6.5 |
| Age < 65 | 609 | 107 | 31.6 |
| Age < 65 | 721 | 34 | 4.9 |
| Age ≥ 65 | 771 | 47 | 40.3 |
Values are n (%) unless stated otherwise.

Shown for pregnant women; error bars are 95% confidence intervals.
4488 participants were included (median age 33 years). Serious adverse events were rare and similar between groups. 3831 participants were included (median age 78 years). Effects were consistent across prespecified subgroups.
Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.65 (95% CI 0.24 to 0.89). length of stay occurred in 15% of the intervention group versus 24% of controls.
Discussion
These findings suggest that SGLT2 inhibitors is associated with better length of stay in pregnant women. Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.
Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded.
Conclusions
SGLT2 inhibitors is a reasonable option for pregnant women to improve length of stay.
References
1. Rahman W, Andersen Y, et al. Delayed cord clamping and emergency department revisits. Pediatrics. 2008;348(10):291-1039.
2. Kowalski B, Nakamura V, et al. Continuous glucose monitoring and glycaemic control. BMJ. 2022;316(6):694-1543.
3. Kowalski S, Silva F, et al. High-flow nasal oxygen and time to diagnosis. N Engl J Med. 2009;232(6):78-1608.
4. Moreau F, Osei B, et al. Frailty screening and patient satisfaction. N Engl J Med. 2010;223(2):729-1153.
5. Okafor S, Yilmaz H, et al. SGLT2 inhibitors and falls. Crit Care Med. 2008;185(8):453-1427.
Appendices
The statistical analysis plan is in the online supplement.